Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

R. Mirza, Mansoor; J. Monk, Bradley; Herrstedt, Jørn; M. Oza, Amit; Mahner, Sven; Redondo, Andrés; Fabbro, Michel; A. Ledermann, Jonathan; Lorusso, Domenica; Vergote, Ignace; Ben-Baruch, Noa; Marth, Christian; Mądry, Radosław; dePont Christensen, René; S. Berek, Jonathan; Dørum, Anne; V. Tinker, Anna; du Bois, Andreas; González-Martı́n, Antonio; Follana, Philippe; B. Benigno, Benedict; Rosenberg, Per; Gilbert, Lucy; Rimel, B.J.; Buscema, Joseph; Balser, John; Agarwal, Shefali; A. Matulonis, Ursula

doi:10.1056/nejmoa1611310

Public

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Published in New England Journal of Medicine • Oct 8, 2016

Authors:

Mansoor R. Mirza

Bradley J. Monk

Jørn Herrstedt

Abstract

BACKGROUND: Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, re...

Subject

Ovarian cancer

Platinum

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!